Cellectis to Report First Quarter Financial Results on May 11, 2026

Rhea-AI Summary

Cellectis (NASDAQ: CLLS) said it will release its first-quarter 2026 financial results for the period ended March 31, 2026 on May 11, 2026 after U.S. market close. The company also said it will not host a conference call; the press release will be posted on its investor website and investor relations can be contacted by email.

News Market Reaction – CLLS

+1.62%

3 alerts

+1.62% Session close to close

$269.10M Market Cap

0.2x Rel. Volume

In the May 5 session, CLLS gained 1.62%, reflecting a mild positive market reaction. Our momentum scanner triggered 3 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timetable for Cellectis’ Q1 2026 financial results, which will be release...

Analysis

This announcement sets the timetable for Cellectis’ Q1 2026 financial results, which will be released on May 11, 2026 after the US close without a follow-up call. Historically, an earlier earnings-date notice coincided with a modest +2.7% move, but the real focus will be on the actual quarterly figures and cash runway. Investors may watch for any subsequent use of the existing Form F-3 shelf and how results track against prior guidance and clinical milestones.

Key Figures

Earnings release date: May 11, 2026 Quarter end date: March 31, 2026

2 metrics

Earnings release date May 11, 2026 Scheduled Q1 2026 results release after US market close

Quarter end date March 31, 2026 End of the first quarter 2026 reporting period

Previous Earnings date Reports

1 past event · Latest: Mar 12 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 12	Earnings date notice	Neutral	+2.7%	Scheduled release of Q4 and full-year 2025 financial results with follow-up call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Historical data for earnings date notices is limited; the last such event saw a modest positive move of +2.7% over 24 hours.

Recent Company History

Over the last several months, Cellectis has mixed news flow including clinical updates, capital structure disclosures, and earnings. Notably, the prior earnings date notice on Mar 12, 2026 preceded reporting of full year 2025 results and coincided with a +2.7% 24-hour move. Other recent items included pivotal trial data and financial updates, indicating investors balance clinical progress with ongoing losses and funding runway when reacting to news.

Key Terms

clinical-stage biotechnology, gene-editing, cell and gene therapies

3 terms

clinical-stage biotechnology medical

"a clinical-stage biotechnology company using its pioneering gene-editing"

Clinical-stage biotechnology refers to biotechnology companies that are in the process of testing new medical treatments or drugs in human trials. This stage is crucial because it indicates that these treatments have shown enough promise in earlier research to be evaluated for safety and effectiveness in people. For investors, it signals a key phase where potential breakthroughs are being tested, but also involves higher risk since the outcomes are still uncertain.

gene-editing medical

"using its pioneering gene-editing platform to develop life-saving cell"

Gene-editing is a set of laboratory techniques that change an organism’s DNA by adding, removing or altering specific genetic instructions—think of it as editing words in a document to fix a sentence. For investors, it matters because these tools can create new treatments, improve agricultural crops or reduce manufacturing costs, potentially driving product value, regulatory risk, research milestones and long-term revenue prospects for companies involved.

cell and gene therapies medical

"platform to develop life-saving cell and gene therapies, today announced"

Cell and gene therapies are advanced medical treatments that aim to repair or replace damaged cells or genes within the body to treat diseases. They hold the potential to deliver long-lasting or even curative effects, similar to fixing a broken part of a machine rather than just covering up the problem. For investors, these therapies represent a rapidly growing area with the promise of transforming healthcare and creating significant market opportunities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

NEW YORK, May 04, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced that it will report financial results for the first quarter 2026 ending March 31, 2026 on Monday, May 11, 2026 after the close of the US market.

The press release will be available in the Investors section of Cellectis’ website: https://www.cellectis.com/en/investors/press-releases/

Cellectis will not host a conference call to discuss these results. Our investor relations team remains available for questions at investors@cellectis.com

About Cellectis

Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit www.cellectis.com and follow Cellectis on LinkedIn and X.

For further information on Cellectis, please contact:

Media contacts:

Pascalyne Wilson, Director, Communications, +33 (0)7 76 99 14 33, media@cellectis.com
Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93

Investor Relations contact:

Arthur Stril, Chief Financial Officer & Chief Business Officer, investors@cellectis.com

Attachment

• PRESS RELEASE_Q1 earnings announcement

FAQ

When will Cellectis (CLLS) report Q1 2026 financial results?

Cellectis will report Q1 2026 results on May 11, 2026 after U.S. market close. According to Cellectis, the release will cover the quarter ended March 31, 2026 and will be posted on the company's investor website.

Will there be a conference call for Cellectis Q1 2026 results (CLLS)?

No, Cellectis will not host a conference call to discuss Q1 2026 results. According to Cellectis, management will publish the press release online and investor relations remain available via the provided email for questions.

Where can investors find the Cellectis (CLLS) Q1 2026 press release?

The Q1 2026 press release will be available in the Investors section of Cellectis' website. According to Cellectis, the release will be posted at the company's investor press releases page after the market close on May 11, 2026.

Who should investors contact with questions about Cellectis Q1 2026 results (CLLS)?

Investors can contact Cellectis' investor relations team via email at investors@cellectis.com. According to Cellectis, the investor relations team will respond to questions since no conference call is scheduled for the Q1 2026 release.

What period do the Cellectis (CLLS) Q1 2026 results cover?

The Q1 2026 results cover the quarter ended March 31, 2026. According to Cellectis, the company will report financial results for that period on May 11, 2026 after the U.S. market close.